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Abstract: Vedolizumab, a monoclonal antibody directed against integrin α4β7, is an effective 
treatment for inflammatory bowel diseases. However, a significant number of patients do not 
achieve steroid-free clinical remission in the first year of treatment. An early identification of these 
patients is one of the most important challenges for clinicians and offers the possibility of 
therapeutic optimization in order to personalize biological therapy. The aim of our study was to test 
the prediction ability of interleukin (IL)-6 and -8 of clinical response after 12 months of therapy with 
vedolizumab (T2). We performed a prospective, multicentre study in patients affected by 
inflammatory bowel disease by analysing cytokines level before starting vedolizumab (T0) and after 
10 weeks of therapy (T1). In the overall cohort (n = 54), IL-8 decrease > 2.6 pg/mL in the first 10 weeks 
of therapy was able to predict clinical response (area under the curve (AUC) = 0.70, sensitivity = 
66%, specificity = 75%, p = 0.010), negative C-reactive protein (CRP) (AUC = 0.71, sensitivity = 64%, 
specificity = 80%, p = 0.009) and calprotectin < 250 mg/kg (AUC = 0.69, sensitivity = 64%, specificity 
= 78%, p = 0.030) after 44 weeks of therapy. In patients with ulcerative colitis (n = 40), baseline IL-8 
values > 8.6 pg/mL and a decrease of IL-6 values > 0.4 pg/mL from T0 to T1 were significant and 
independent predictors of clinical response after 12 months of vedolizumab therapy (odds ratio 
(OR) = 6.96, 95% CI 1.27—38.22, p = 0.026 and OR = 7.29, 95% CI 1.42—37.50, p = 0.017, respectively). 
In patients with Crohn’s disease (n = 14), baseline IL-8 values > 8.6 pg/mL and baseline IL-6 values 
> 1.6 pg/mL allowed the identification of patients achieving negative CRP at T2 (AUC = 0.75, 
sensitivity = 74%, specificity = 76%, p < 0.001) and patients with faecal calprotectin values < 250 
mg/kg at T2 (AUC = 0.71, sensitivity = 78%, specificity = 63%, p = 0.004). In conclusion, our study 
highlights a potential clinical role of serum cytokine levels for the prediction of clinical and 
biochemical steroid-free response in patients treated with vedolizumab. 
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1. Introduction 
Inflammatory bowel diseases (IBD) are chronic gastrointestinal disorders consisting of two main 
entities, ulcerative colitis (UC) and Crohn’s disease (CD), both characterized by an immune-mediated 
pathogenesis and a clinical relapsing course [1,2]. 
In the last two decades, a more comprehensive understanding of the cytokine pathways 
involved in the pathogenesis of IBD allowed the development of new treatment strategies that led to 
reduced use of corticosteroids [3]. Vedolizumab (VDZ) is an important therapeutic option for IBD 
patients [4], due to a different mechanism of action, as compared to nonbiological therapeutic 
approaches or anti-tumour necrosis factor (TNF) agents [5]. This monoclonal antibody, which binds 
α4β7-integrin expressed in a subset of T-lymphocytes, prevents the adherence and diapedesis of the 
latter through the mucosal vascular addressin cell adhesion molecule (MAdCAM)-1, expressed only 
in the gut endothelium [6]. Despite a satisfactory clinical development programme, real-life studies 
reveal that only 40% of patients treated with VDZ achieve clinical remission [7]. 
Therefore, it is crucial to identify biomarkers able to predict and monitor therapeutic success in 
order to tailor individualized treatment strategies. The most used biomarker in IBD practice is faecal 
calprotectin, but it reflects only a non-specific anti-inflammatory response [8,9]. For this reason, an 
analysis of cytokine levels in patients with IBD could be useful to predict the pharmacological 
response to treatment with biological drugs, such as VDZ. In this perspective, the most relevant 
cytokines involved in the pathophysiology of IBD [10–12] and studied as possible biomarkers of 
therapeutic response [13–16] are interleukin (IL)-6 and IL-8. Indeed, in a previous monocentre study 
involving patients with UC and CD treated with different types of biologics drugs, we observed that 
IL-6 reduction from baseline to 10 weeks of treatment was able to broadly predict clinical response at 
12 months of therapy [17].Here, we aimed at investigating the prediction ability of IL-6 and -8 of 
clinical response after 10 weeks and after 12 months of therapy with VDZ. 
2. Materials and Methods 
We performed a prospective, multicentre study at the Gastroenterology Unit of “Città della 
Salute e della Scienza di Torino”, Italy and at IBD Unit, Pisa University Hospital, Pisa, Italy. From 
January 2018 to January 2019 we recruited consecutive patients: (1) affected by IBD with indications 
to treatment with VDZ; (2) older than or equal to 18 years; (3) who agreed to sign the informed 
consent to participate in the study. We treated patients with moderate-to-severe disease activity or 
steroid-dependent disease with previous failure or intolerance to thiopurines with VDZ [18,19]. 
Exclusion criteria were: (1) refusal to participate to the study. 
Clinical history, data on physical examination, recent biochemical examinations and signed 
informed consent for the purpose of enrolment in the study, were collected. All patients were treated 
with a total dose of 300 mg by infusion at 0–2–6 weeks interval as induction, and every 8-weeks 
thereafter during the year. In particular, none of the patients affected by CD was treated with the 
infusion at week 10 and none was treated with a 4- or 6-weeks maintenance regimen. Before starting 
VDZ therapy, venous blood was collected. The blood samples were associated with a numerical 
identification code and stored frozen at −80 °C. Two blood samples were collected from each IBD 
patient, the first before the start of VDZ therapy (T0) and the second after 10 weeks of treatment (T1). 
IL-6 and IL-8 were measured in serum samples by Bio-Plex® Multiplex Immunoassay (Bio-Rad 
Laboratories, Pleasanton, CA, USA) on Luminex® 200 system (Luminex Corporation, Austin, TX, 
USA) [20]. Individual standard curves were generated for each cytokine; results were given in pg/mL. 
2.1. Description of the Cohort 
The cohort included 54 patients. The epidemiological characteristics, clinical, biochemical and 
endoscopic activity, medications of the recruited patients are reported in Table 1. 
All patients with CD were previously treated with anti-TNF therapy (adalimumab), except one 
due to contraindication to these drugs; 24 patients with UC were previously treated with anti-TNF 
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therapy (infliximab), 16 were naive to biological therapies. No patients were previously treated with 
ustekinumab or tofacitinib. 
The primary aim was to evaluate the prediction ability of the trends observed in IL-6 and IL-8 
levels between T0 and T1 of clinical response at twelve months of therapy. The secondary goals were 
to evaluate: (1) the prediction ability of IL-6 and IL-8 at T0 of clinical response at T2; (2) the prediction 
ability of baseline levels and trends of IL-6 and IL-8, of negative C-reactive protein (CRP) and 
calprotectin values < 250 mg/kg at twelve months of therapy; (3) sub-analyses for CD and UC. 
Clinical response to VDZ therapy was defined as a decrease in the Harvey-Bradshaw index 
(HBI) score greater than or equal to 3 (or HBI ≤ 4 at month twelve) or in the partial Mayo (pMAYO) 
score greater than or equal to 2 (or pMAYO ≤ 1 at month twelve), in absence of corticosteroid therapy 
and with ongoing VDZ therapy, in agreement with literature [21]. 
The study followed the principles of the Declaration of Helsinki and was approved by the local 
ethical committee (Comitato Etico Interaziendale A.O.U. Città della Salute e della Scienza di Torino—
A.O. Ordine Mauriziano—A.S.L. Città di Torino) (approval code 0056924). 
Table 1. Epidemiological features, clinical activity according to Harvey-Bradshaw index (HBI) and 
partial MAYO (pMAYO) score, biochemical activity and medications at baseline of the study 
population. 
Characteristics IBD CD UC 
Number of patients 54 14 40 
Age (years), median (range) 48 (18–80) 46 (18–80) 56 (20–76) 
Sex (M/F) 14/40 10/4 10/30 
Smoke (current/never/ex) 8/25/21 3/8/3 5/17/18 
Years of illness, median (range) 14 (2–33) 18 (3–33) 11 (2–27) 
Montreal classification - - - 
(CD: L1/L2/L3/L4; UC: E1/E2/E3)  1/1/12/1 3/16/21 
Clinical activity (mean, 95% CI) 
(CD: HBI; UC: pMAYO) 
 7.1 (5.2–9) 5.3 (4.6–5.9) 
Biochemical activity - - - 
Faecal calprotectin (mg/kg), 559 (382–816) 1620 (519–5064) 463 (314–683) 
(geometric mean, 95% CI) - - - 
CRP (mg/L),  9.3 (6.9–12.8) 8.4 (1.5–46.39 9.8 (6.9–13.7) 
(geometric mean, 95% CI) - - - 
ESR (positive/negative) 33/21 6/8 27/13 
Concomitant medications  - - - 
Mesalazine (yes/no, %) 48/6 (88.9%) 9/5 (64.3%) 39/1 (97.5%) 
Systemic corticosteroids (yes/no, %) 33/21 (61.1%) 9/5 (64.3%) 24/16 (60.0%) 
Azathioprine (yes/no, %) 8/46 (14.8%) 2/12 (14.3%) 6/34 (15.0%) 
Abbreviations: male (M), female (F), inflammatory bowel disease (IBD); Crohn’s disease (CD); 
ulcerative colitis (UC); ileum (L1); colon (L2); ileum + colon (L3); upper gastrointestinal (L4); rectum 
(E1); left side (E2); extensive (E3); confidence interval (CI); C-reactive protein (CRP); erythrocyte 
sedimentation rate (ESR); higher than the upper limit of the reference (positive). 
2.2. Statistical Analysis 
Continuous variables were reported as mean (range or 95% confidence interval (CI)), geometric 
mean or as median depending on data distribution. The normality of the data was evaluated by 
D’Agostino-Pearson test. We performed an intention-to-treat analysis and included all the patient 
that started VDZ in the final analysis. The comparison of continuous variables between independent 
groups was performed by independent samples t-test. The comparison of continuous paired 
measurements was carried out by t-student test for paired measurements or by Wilcoxon test, 
depending on data distribution. The comparison of paired, dichotomous qualitative variables was 
carried out by McNemar test. Receiver operating characteristic (ROC) curve analysis for used to test 
the ability of IL-6 and IL-8 to discriminate between patients who achieved the outcomes from those 
who did not. Diagnostic accuracy has been reported as area under the curve (AUC) value. Logistic 
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regression was performed to derive the odds ratio (OR), with its 95% confidence interval, as a 
measure of the strength of association between two variables. 
Since no previous studies have analysed the ability of IL-6 and IL-8 to predict clinical response 
to VDZ in patients with CD and UC, a priory calculation of the power of the study has not been 
possible. We chose to include twice the number of patients recruited in the most similar study (27 
patients; cytokines’ prediction ability of mucosal healing in UC [16]).  
A p-value of less than 0.05 was considered significant. Statistical analysis was performed with 
MedCalc Statistical Software version 18.9.1 (MedCalc Software bvba, Ostend, Belgium; 
http://www.medcalc.org; 2018). 
3. Results 
IL-6 and IL-8 baseline values are reported in Table 2. 
Table 2. IL-6 and IL-8 baseline values. 
Parameters Patients with CD (n = 14) Patients with UC (n = 40) p-Value 
IL-6 (pg/mL), (geometric mean, range) 2.1 (0.6–7.1) 2.5 (0.2–29.8) 0.770 
IL-8 (pg/mL), (geometric mean, range) 3.4 (OOR–29.7) 6.7 (OOR–61.4) 0.380 
Abbreviations: interleukin (IL), Crohn’s disease (CD), ulcerative colitis (UC), out of range (OOR). 
The trends of the parameters at 3 and 12 months in the overall cohort and according to type of 
disease are reported in Table 3. 
Table 3. Trend of the parameters at 3 and 12 months in the overall cohort and according to type of 
disease (CD and UC). 
Parameters T0 T1 
p-Value 
(T1 vs. 
T0) 
T2 
p-Value 
(T2 vs. 
T0) 
Total cohort (n = 54)      
Calprotectin (mg/kg), 
(geometric mean, 95% CI) 
559 (382–816) 205 (129–325) < 0.001 151 (83–275) < 0.001 
CRP (mg/L), 
(geometric mean, 95% CI) 
9.3 (6.9–12.8) 5.1 (3.4–7.6) 0.007 4.4 (2.9–6.8) 0.006 
ESR (positive/negative) 33/21 29/25 0.050 26/28 0.020 
IL-6 (pg/mL), 
(median, 95% CI) 2.5 (1.5–3.5) 1.4 (1.1–1.9) 0.007 N/P N/A 
IL-8 (pg/mL), 
(median, 95% CI) 
8.2 (5.2–12.2) 8.0 (5.1–9.6) 0.060 N/P N/A 
CD (n = 14)      
Calprotectin (mg/kg), 
(geometric mean, 95% CI) 
1620 (519–
5064) 
608 (173–
2129) 
0.039 
414 (45–
3799) 
0.017 
CRP (mg/L), 
(geometric mean, 95% CI) 
8.4 (1.5–46.3) 6.4 (2.0–20.3) 0.619 4.4 (1.0–18.8) 0.039 
ESR (positive/negative) 6/8 5/9 1.000 4/10 0.500 
IL-6 (pg/mL), 
(median, 95% CI) 
1.6 (0.9–6.0) 2.0 (0.2–16.5) 0.414 N/P N/A 
IL-8 (pg/mL), (median, 95% 
CI) 
5.8 (1.9–14.6) 8.9 (3.5–14.4) 0.970 N/P N/A 
UC (n = 40)      
FC (mg/kg), 
(geometric mean, 95% CI)  
463 (314–683) 169 (103–277) 0.001 134 (70–255) <0.001 
CRP (mg/L), 
(geometric mean, 95% CI) 
9.8 (6.9–13.7) 4.8 (3.1–7.5) 0.007 4.4 (2.8–7.0) 0.013 
ESR (positive/negative) 27/13 24/16 0.250 22/18 0.063 
IL-6 (pg/mL), 
(median, 95% CI) 
2.5 (1.4–3.4) 1.4 (1.2–1.9) 0.009 N/P N/A 
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IL-8 (pg/mL), 
(median, 95% CI) 
8.3 (6.2–14.0) 8.0 (5.0–9.6) 0.032 N/P N/A 
Abbreviations: Before therapy (T0); after 10 weeks (T1); after twelve months (T2); Crohn’s disease 
(CD); C-reactive protein (CRP); erythrocyte sedimentation rate (ESR); interleukin (IL); not performed 
(N/P); not applicable (N/A); ulcerative colitis (UC). 
IL-6 values from T0 to T1 did not change in CD (median value from 1.6 to 2.0 pg/mL, p = 0.414) 
and decreased in UC (median value from 2.5 to 1.4 pg/mL, p = 0.009); IL-8 values did not change in 
CD (median values from 5.8 to 8.9 pg/mL, p = 0.970) and decreased in UC (median values from 8.3 to 
8.0 pg/mL, p = 0.032). IL-6 and IL-8 variation from T0 to T1 classified according to treatment response 
and to type of disease (CD or UC) are depicted in Figure 1. 
 
Figure 1. IL-6 and IL-8 variation from T0 to T1 in patients with CD (A) (C) and UC (B) (D) according 
to clinical response to treatment. 
Seven patients stopped VDZ during the year due to drug failure. These patients, as stated in the 
Material and Methods, were considered as failure of primary outcome (clinical response to VDZ 
therapy was defined as a decrease in the HBI score greater than or equal to 3 (or HBI ≤ 4) or in the 
pMAYO score greater than or equal to 2 (or pMAYO ≤ 1), in absence of corticosteroid therapy and 
with ongoing VDZ therapy). At T2 33/54 (61.1%) patients achieved clinical response. In the overall 
cohort of patients with IBD, we observed that IL-8 reduction > 2.6 pg/mL from T0 to T1 was able to 
discriminate between patients who responded to therapy at T2 from those who did not (AUC = 0.70, 
sensitivity = 66%, specificity = 75%, p = 0.010). Baseline IL-8 values > 8.6 pg/mL and IL-8 reduction > 
2.6 pg/mL from T0 to T1 were able to identify patients achieving CRP negativization at T2 (AUC = 
0.70, sensitivity = 74%, specificity = 76%, p = 0.021 and AUC = 0.71, sensitivity = 64%, specificity = 80%, 
p = 0.009, respectively). Baseline IL-6 values > 1.6 pg/mL and IL-8 reduction > 2.6 pg/mL from T0 to 
T1 were able to identify patients achieving faecal calprotectin values < 250 mg/kg at T2 (AUC = 0.70, 
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sensitivity = 78%, specificity = 74%, p = 0.020 and AUC = 0.69, sensitivity = 64%, specificity = 78%, p = 
0.030, respectively). 
In patients with CD, we observed that baseline IL-8 values > 8.6 pg/mL allowed the identification 
of patients achieving negative CRP at T2 (AUC = 0.75, sensitivity = 74%, specificity = 76%, p < 0.001) 
while baseline IL-6 values > 1.6 pg/mL identified patients with faecal calprotectin values < 250 mg/kg 
at T2 (AUC = 0.71, sensitivity = 78%, specificity = 63%, p = 0.004). 
In patients with UC, baseline IL-6 values > 1.6 pg/mL allowed the identification of patients 
achieving a clinical response at 12 months of therapy (AUC = 0.70, sensitivity = 79%, specificity = 60%, 
p = 0.012) and faecal calprotectin values < 250 mg/kg at T2 (AUC = 0.71, sensitivity = 79%, specificity 
= 60%, p = 0.006). Baseline IL-8 values > 8.6 pg/mL identified patients who achieved a clinical response 
at 12 months of treatment (AUC = 0.70, sensitivity = 58%, specificity = 80%, p = 0.010), negative CRP 
at T2 (AUC = 0.73, sensitivity = 68%, specificity = 78%, p = 0.002) and faecal calprotectin values < 250 
mg/kg at T2 (AUC = 0.70, sensitivity = 65%, specificity = 75%, p = 0.011). IL-6 reduction > 0.4 pg/mL 
from T0 to T1 led to the identification of patients who achieved a clinical response at 12 months of 
treatment (AUC = 0.73, sensitivity = 73%, specificity = 73%, p = 0.003), negative CRP at T2 (AUC = 0.72, 
sensitivity = 74%, specificity = 71%, p = 0.004) and faecal calprotectin values < 250 mg/kg at T2 (AUC 
= 0.78, sensitivity = 75%, specificity = 80%, p < 0.001). IL-8 reduction > 2.6 pg/mL from T0 to T1 
identified patients achieving a clinical response at 12 months of treatment (AUC = 0.72, sensitivity = 
64%, specificity = 80%, p = 0.004), negative CRP at T2 (AUC = 0.75, sensitivity = 68%, specificity = 82%, 
p < 0.001) and faecal calprotectin values < 250 mg/kg at T2 (AUC = 0.73, sensitivity = 65%, specificity 
= 80%, p = 0.003) (Figure 2). 
 
Figure 2. ROC curve of baseline IL-6 values, baseline IL-8 values, IL-6 reduction from T0 to T1 and 
IL-8 reduction from T0 to T1 for the identification of patients with UC that achieved a clinical response 
to therapy at T2. 
To confirm that the event was specific to VDZ treatment, we performed a sub-analysis of cases 
with start or dose escalation of systemic corticosteroid within 2-weeks before or after the start of VDZ 
therapy. We excluded one patient from CD cohort and three patients from UC cohort (in total four 
patients from the whole IBD cohort). All the analyses confirmed that the effects observed were due 
to VDZ treatment and not caused by the steroid’s treatment. 
By logistic regression analysis, we observed that baseline IL-6 values > 1.6 pg/mL (OR = 5.70, 
95% CI 1.37—23.76, p = 0.017), baseline IL-8 values > 8.6 pg/mL (OR = 5.60, 95% CI 1.25—25.17, p = 
0.025), IL-6 reduction > 0.4 pg/mL (OR = 7.33, 95% CI 1.67—32.21, p = 0.008) and IL-8 reduction > 2.6 
pg/mL (OR = 7.00, 95% CI 1.51—32.48, p = 0.013) were significantly associated to clinical response at 
T2 in patients with UC, while neither CRP reduction (OR = 0.40, 95% CI 0.08—1.89, p = 0.248) nor 
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faecal calprotectin reduction (OR = 4.52, 95% CI 0.85—24.11, p = 0.077) predicted clinical response. By 
multiple stepwise logistic regression analysis, only baseline IL-8 values > 8.6 pg/mL (OR = 6.96, 95% 
CI 1.27—38.22, p = 0.026) and IL-6 reduction > 0.4 pg/mL (OR = 7.29, 95% CI 1.42—37.50, p = 0.017) 
resulted significant and independent predictors of clinical response at T2. This result was further 
confirmed following adjustment for disease activity and extent (E3, n = 21, versus E1, n = 3 plus E2, n 
= 16) (Table 4). 
Table 4. Adjusted OR of variables included in the multivariate regression analysis for the prediction 
of clinical response at T2 in patients with UC. 
Variables OR, 95% CI p-Value 
Baseline IL-8 > 8.6 pg/mL 14.74, 1.78–122.14 0.013 
IL-6 reduction > 0.4 pg/mL 10.81, 1.58–73.68 0.015 
Disease activity 0.70, 0.21–2.28 0.550 
Disease extent (E3) 0.18, 0.02–1.35 0.097 
Abbreviations: interleukin (IL), odds ratio (OR). 
4. Discussion 
VDZ is effective for the treatment of IBD, as demonstrated by several real-life studies [22–24]. 
However, a considerable number of patients, ranging between 50 and 75%, do not achieve steroid-
free clinical remission during the first year of treatment [22–24]. An early identification of potentially 
non-responding patients is one of the most important challenges for clinicians, which may lead to a 
possible therapeutic optimization in order to personalize biological therapy. 
In recent years, several studies were conducted in order to identify reliable biomarkers of 
therapeutic effectiveness. At present, the only parameter that predicts a worst therapeutic outcome 
to VDZ therapy with reasonable confidence is the previous exposure to anti-TNF drugs [25,26]. 
Moreover, patients with severe clinical activity at baseline are less likely to respond to VDZ [26], as 
well as patients who achieve a clinical response at week 6 often achieve steroid-free clinical remission 
after one year [22]. 
Moving to laboratory biomarkers, a prospective real-life study showed that a decrease in faecal 
calprotectin at week 14 was associated with clinical remission at one year. However, data regarding 
its use as a prospective biomarker in VDZ-treated patients are conflicting, since a post-hoc analysis 
of GEMINI-I trial showed that faecal calprotectin levels after the induction of VDZ therapy are not 
able to predict endoscopic response [27]. Conversely, faecal calprotectin showed in several studies in 
IBD setting a reliable correlation with endoscopic activity [28–30]. 
CRP is the most used biomarker in IBD, but a recent review showed that it is not reliable in 
predicting therapeutic outcome to VDZ [31]. On the other hand, Buer et al. [32] displayed how higher 
levels of CRP at baseline were correlated with lower plasma levels of VDZ at week 14, and this finding 
is particularly important since there are several studies that showed how the measurement of drug 
levels could be used as marker of therapeutic outcome. Indeed, higher levels of VDZ are associated 
with clinical, biochemical and endoscopic remission [33–35], but also with treatment persistency [36]. 
In this perspective, Boden et al. [37] have proposed the use of VDZ trough levels, α4β7 baseline 
expression and its receptor as possible biomarkers of therapeutic response, while Battat et al. [38] 
showed a correlation between serum α4β7 integrin concentration and therapeutic outcome. 
Unfortunately, these analyses are not widely available, and their use in clinical practice is unlikely. 
The evaluation of serum cytokine profiles could represent a reliable and non-invasive tool to 
predict the therapeutic efficacy of biological drugs [39]. Our study showed that serum cytokines IL-
6 and IL-8 could have a role in predicting therapeutic outcome to VDZ. In particular, the most 
important finding of our study was the association between baseline IL-8 values and IL-6 reduction 
in the first three months of treatment with clinical response at twelve months in UC patients, but not 
in CD, even at multiple stepwise logistic regression analysis. Interestingly, the reduction of CRP or 
faecal calprotectin in the same timeframe was not able to predict clinical response. Notably, at 
multivariate regression analysis, baseline IL-8 values and IL-6 reduction remained the only 
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parameters associated with clinical response, taking into account also the severity and extent of 
disease. The results of the present study are in partial agreement with a previous single-centre study 
involving patients with IBD treated with different types of biologic drugs [17]; in both studies, the 
reduction of IL-6 in course of therapy was associated to the clinical response at 12 months of 
treatment. Herein, focusing on patients undergoing VDZ, we found a significant predictive value 
also for baseline IL-8 serum levels. 
A recent study [16] in a small population of UC patients treated with VDZ showed that the 
decrease in IL-6 and IL-8 over the first 6 weeks of treatment correlated with mucosal healing after 
twelve months of treatment. Consistently, in the present study we showed that a decrease > 0.4 pg/mL 
of IL-6 and > 2.6 pg/mL of IL-8 levels in the first three months predicted faecal calprotectin < 250 
mg/kg at twelve months in patients affected by UC. Although endoscopic assessment is currently 
recognized as the best therapeutic outcome [21], faecal calprotectin < 250 mg/kg is commonly 
considered as marker of endoscopic remission, both in paediatric [29] and adult patients [28]. Of note, 
this threshold was chosen even in the famous CALM trial where treatment escalation was decided 
based on faecal calprotectin levels > 250 mg/kg [40]. Another important finding of the present study 
is the correlation between baseline IL-6 and clinical response at twelve months in UC patients; 
although a trend was highlighted in the previous study [16] statistical correlation was not achieved 
probably due to the smaller number of patients. Moreover, the present study showed that the 
decrease in IL-6 and IL-8 levels in the first three months of therapy was correlated to normal values 
of CRP at twelve months, which was not evaluated in the previous study [16]. Hence, our results 
provided evidence in a larger cohort of patients in confirming that the decrease of these cytokines 
was able to predict a complete biochemical response in VDZ-treated patients with UC, but not in CD. 
Although additional evidences are necessary to draw definitive conclusions, the present study 
allowed to demonstrate the presence of a different behaviour of serum cytokines useful to predict 
therapeutic response in UC compared to CD. IL-8, mainly released by macrophages and epithelial 
cells, exerts its pro-inflammatory functions by promoting the chemiotactic attraction of neutrophils 
into the inflammatory site [41]. In UC, unrestricted neutrophil activation may cause significant tissue 
damage that further fuel chronic inflammation [42]. By contrast, in CD, defective neutrophils may 
not be able to limit invasion by microorganisms, hence leading consequently to an uncontrolled 
inflammatory reaction [43]. 
A study by Rodriguez-Perálvarez et al. [44] in UC showed that serum levels of this cytokine 
were correlated with disease activity in terms of clinic, endoscopic and histologic findings. Moreover, 
lower IL-8 levels have been found in non-ulcerated mucosa of UC patients, as compared to mucosal 
ulcerations [45]. The decrease of IL-8 more consistent in therapy responders than in non-responders 
to VDZ treatment showed in the present study could be explained by an increased expression of α4β7 
integrin driven by this cytokine. Indeed, Boden et al. [37] found higher basal α4β7 expression on CD4 
and CD8 T-cells, which are activated by IL-8, in responders as compared with non-responders to 
VDZ therapy. Furthermore, a recent study by Zeissig et al. [46] suggested that the therapeutic efficacy 
of VDZ could be related to an effect on cells of mucosal innate immunity, such as macrophages, which 
are the main producers of IL-8. Conversely, the role of IL-8 in predicting therapeutic response seems 
to be less important in CD [47]. 
Concerning CD patients, although baseline serum levels of IL-6 and IL-8 were not able to 
discriminate clinical response, baseline IL-8 values > 8.6 pg/mL were able to predict a negative CRP 
value at twelve months. On the other hand, baseline IL-6 values > 1.62 pg/mL predicted faecal 
calprotectin < 250 mg/kg at twelve months, Concerning CRP, this could be expected, according to 
several studies that showed how CRP is more helpful in CD than in UC [48,49], and the correlation 
between IL-8 and this biomarker has been demonstrated [50] Conversely, the correlation between IL-
6 and faecal calprotectin could be surprisingly, since faecal calprotectin is more reliable in UC than 
in CD [8]. However, IL-6 is a pleiotropic cytokine produced by innate immune and supporting 
stromal cells and activates adaptive T and B effector cells [51]. Indeed, IL-6 levels were demonstrated 
to be significantly higher in CD patients, compared to those with UC [52]. In this perspective, the 
assessment of IL-6 levels was proposed in several studies in order to predict therapeutic outcome in 
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CD. However, the results were conflicting: Billiet et al. [53] showed that IL-6 concentrations decreased 
significantly in responders compared to primary non-responders to infliximab therapy, whereas 
Yarur et al. [47] reported that the assessment of IL-6 and IL-8 levels is not reliable in predicting 
therapeutic effectiveness of anti-TNF drugs in CD. 
Our study showed a preliminary evidence that higher levels of IL-6 at baseline are associated 
with a better outcome of VDZ therapy. This is in line with the trend showed in our previous study 
conducted in UC patients, aimed at evaluating the correlation between serum cytokines and mucosal 
healing [16]. On the other hand, a study by Soendergaard et al. [15] showed a correlation between 
lower levels of IL-6 at baseline and clinical response to VDZ after the induction. This difference could 
be related to the different endpoint: clinical response after the induction is certainly different in 
comparison with biochemical remission in terms of faecal calprotectin, which could be a surrogate 
marker of mucosal healing. Moreover, the study by Soendergaard et al. [15] included only IBD 
patients with a previous exposure to anti-TNF drugs: several studies demonstrated how VDZ is less 
effective in this population [24,26], and, furthermore, anti-TNF drugs are known to reduce IL-6 levels 
[14,54]. IL-6 is produced by innate immune and supporting stromal cells and activates adaptive T 
and B effector cells [51]. Following the findings by Zeissig et al. [46] described above, higher levels of 
IL-6 could be related to high activity of innate immunity in patients treated with VDZ. In this 
perspective, it is reasonable that a drug that exerts its function trough a modulation of innate 
immunity is more effective in patients with a high activation of the molecules involved in this process. 
However, it is worthy to note that additional evidence from other studies with a greater number of 
patients is needed to reach a reliable conclusion on the role of IL-6 in VDZ-treated patients. 
This main strength of this study is the strong statistical correlation, confirmed at multivariate 
analysis, between clinical response to VDZ in IBD patients and the levels of IL-8 at baseline and the 
trend of IL-6. Moreover, the correlation with normal CRP and faecal calprotectin < 250 mg/kg could 
reflect a biochemical remission as well as an endoscopic response. Another important finding of this 
study, never demonstrated before, is the difference in terms of reliability of IL-6 and IL-8 in 
comparison with CRP or faecal calprotectin as prospective biomarkers of clinical response to VDZ, 
which could suggest the assessment of these cytokines in clinical practice, if confirmed in other 
studies with larger cohorts of UC patients. The difference highlighted between CD and UC patients 
in the present study is also particularly interesting and paves the way for future studies aimed at 
corroborating this preliminary evidence. Lastly, it is worthy to mention that we have included 
consecutive patients eligible to treatment with VDZ, reflecting a real-life practice. 
The present study has some limitations. Firstly, the number of CD patients is relatively low; in 
this perspective, the results should be intended as exploratory in this specific cohort. Moreover, the 
assessment of VDZ trough levels could be interesting in order to evaluate the correlation between 
serum cytokines and VDZ pharmacokinetics, although this evaluation is not widely performed in 
real-life practice. Lastly, an endoscopic assessment at twelve months would improve the significance 
of the results, although faecal calprotectin < 250 mg/kg is currently well recognized as a marker of 
endoscopic remission [28,30]. However, performing colonoscopies would allow to collect biopsies, in 
order to evaluate even histological healing and tissue cytokine levels, which could be another 
important weakness of our study. On the other hand, we wish to note that the primary aim of this 
study, which was conceived as an exploratory search, was to identify a reliable and easy-to-perform 
biomarker capable to predict the clinical response to VDZ as early as possible. For this reason, we 
decided to focus our attention only on serum biomarkers, as blood is clearly far more accessible and 
less invasive than endoscopic evaluation with the collection of tissue bioptic specimens. 
5. Conclusions 
In conclusion, in patients with UC treated with VDZ, the assessment of serum levels of IL-6 and 
IL-8 values at baseline and after10 weeks of treatment may allow the prediction of clinical response 
at 12 months of therapy and thus may help clinicians to tailor personalized treatment strategies. 
Further studies are needed to validate these results on larger groups of patients with IBD undergoing 
treatment with VDZ. 
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